A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma.

Trial Profile

A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Figitumumab (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2012 This trial is recruiting in France and has been completed in Belgium.
    • 03 Mar 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top